On Feb. 8, 2021, NanoViricides announced that its broad-spectrum anti-coronavirus drug candidate for the treatment of COVID-19 infections…
On Feb. 8, 2021, Tonix Pharmaceuticals announced it had received the written response from the FDA to a…
On Feb. 7, 2021, Oxford University announced that an analysis, submitted as a pre-print prior to peer-review publication,…
On Feb. 5, 2021, the Wellcome Sanger Institute announced that to date it had sequenced 136,383 coronavirus genomes….
On Feb. 5, 2021, Oxford University announced that a preprint of ongoing work to assess effectiveness of Oxfordï¾’s…
On Feb. 4, 2021, T2 Biosystems announced that its T2SARS-CoV-2 Panel – a molecular diagnostic test that detects…
On Feb. 3, 2021, IAVI and Scripps Research announced a phase 1 clinical trial testing a novel vaccine…
On Feb. 3, 2021, an experimental single-dose, intranasal influenza vaccine, was safe and produced a durable immune response…
On Feb. 3, 2021, Bristol-Myers and The Rockefeller University announced an agreement under which Bristol Myers Squibb was…
On Feb. 2, 2021, Oragenics announced that the stabilized pre-fusion spike protein CoV-2 S-2P created by the National…
On Feb. 2, 2021, VBI Vaccines announced that the FDA had accepted its filing of the Biologics License…
On Jan. 29, 2021, Pfizer and BioNTech announced that data from an in vitro study on the capability…
On Jan. 28, 2021, The WHO announced that COVID-19 cases and deaths were surging in Africa as more…
On Jan. 28, 2021, Novavax announced that NVX-CoV2373, its protein-based COVID-19 vaccine candidate, had met the primary endpoint,…
On Jan. 28, 2021, Celsion announced the filing of a provisional U.S. patent application for a novel DNA-based,…
On Jan. 27, 2021, OncoSec Medical announced that it had dosed several subjects in its Phase 1 clinical…
On Jan. 26, 2021, Abbott announced it had received CE Mark for two new uses of its Panbioï¾™…
On Jan. 25, 2021, HHMI investigators reported that cholesterol, the waxy compound better known for clogging arteries, helps…
On Jan. 25, 2021, Nirmidas Biotech announced its second FDA Emergency Use Authorization (EUA) for their COVID-19 rapid…
On Jan. 25, 2021, Oregon Health & Science University (OHSU) announced a new study demonstrated that antibodies generated…
On Jan. 21, 2021, the FDA approved Cabenuva (cabotegravir and rilpivirine, injectable formulation) as a complete regimen for…
On Jan. 21, 2021, NIH researchers announced that after people recover from infection with a virus, the immune…
On Jan. 21, 2021, Janssen Pharmaceutical announced the FDA had approved CABENUVA (consisting of Janssenï¾’s rilpivirine and ViiV…
On Jan. 21, 2021, XBiotech announced that its COVID-19 candidate True Humanï¾™ antibody therapy may also be used…
On Jan. 19, 2021, the Northern Arizona University and TGen, an affiliate of City of Hope, announced results…
On Jan. 19, 2021, ImmunityBio announced it had received authorization from the South Africa Health Products Regulatory Authority…
On Jan. 18, 2021, Quest Diagnostics announced that it has entered into an agreement with the Centers for…
On Jan. 15, 2021, VBI Vaccines announced that results from a Phase 4 study of VBIï¾’s prophylactic 3-antigen…
On Jan. 14, 2021, PerkinElmer announced that its PerkinElmerï¾® Coronavirus Nucleic Acid Detection Kit received Emergency Use Authorization…
On Jan. 14, 2021, Cepheid that Health Canada announced that it had issued Cepheid a medical device license…